DiaMedica Inc.
TSX VENTURE : DMA

DiaMedica Inc.

July 30, 2014 08:00 ET

DiaMedica to Present at InvestMNt Conference on August 6, 2014

MINNEAPOLIS, MINNESOTA--(Marketwired - July 30, 2014) - DiaMedica Inc. (TSX VENTURE:DMA), a clinical stage biopharmaceutical company primarily focused on the development of novel, first-in-class therapies for metabolic disorders, kidney dysfunction and orphan diseases, announced today that the Company will present at the 2014 InvestMNt conference sponsored by CFA Society Minnesota.

The all-day event will take place August 6 at the University of St. Thomas in downtown Minneapolis. The Company will present at 3:45 p.m. CT.

A total of 60 companies from the Upper Midwest and elsewhere are participating in the conference, which is sponsored by the 1,200-member CFA Society and financially supported by more than 25 institutional investment firms and corporate sponsors. For more information and to register, visit http://investmnt.org.

About DiaMedica

DiaMedica Inc. is a publicly traded (TSX VENTURE:DMA) clinical stage biopharmaceutical company primarily focused on the development of novel, first-in-class therapies for metabolic disorders, kidney dysfunction and orphan diseases. DiaMedica's lead clinical stage product, DM199, recombinant human tissue kallikrein-1 protein ("rhKLK-1"), is a novel, first-in-class, therapeutic for the treatment of diabetes mellitus and associated complications. DiaMedica also is developing DM204, a monoclonal antibody program, for glucose control and cardiovascular complications in type 2 diabetes and a companion diagnostic in vitro assay, DMDx, utilizing the detection of tissue kallikrein-1 protein ("KLK-1") as a potential biomarker in human urine to identify diabetic kidney disease patients who are most likely to respond to a therapeutic regimen that includes DM199.

The Company is listed on the TSX Venture Exchange in Canada under the trading symbol 'DMA'.

About InvestMNt

Now in its 3rd year, InvestMNt is a one-day conference developed by institutional investors at mutual funds, private money management firms, retirement plan sponsors and other wealth management entities. Last year's event featured C-level executives from 48 presenting companies, plus more than 200 one-on-one meetings with senior management. More than 350 people attended last year's event, which was conceived and implemented by the CFA Society of Minnesota.

About CFA Society of Minnesota

Founded in 1952, the CFA Society of Minnesota is one of the oldest chapters of the prestigious CFA Institute, issuer of the Chartered Financial Analyst designation. The CFA Society of Minnesota is the 21st largest society of analysts among the 143 member societies and affiliates worldwide. For 60 years, CFA Minnesota has played a vital role within the Twin Cities investment community.

FORWARD-LOOKING STATEMENTS

The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica's expectations, including the intended use of the net proceeds of the Offering, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in DiaMedica's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. DiaMedica undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events, unless required by law. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this press release.

Contact Information